Suppr超能文献

晚期食管癌放化疗中选择性淋巴结照射剂量的评估

Evaluation of Exposure Doses of Elective Nodal Irradiation in Chemoradiotherapy for Advanced Esophageal Cancer.

作者信息

Tamamura Hiroyasu, Hasatani Kenkei, Matsumoto Sae, Asahi Satoko, Tatebe Hitoshi, Sato Yoshitaka, Matsusita Keiichiro, Tameshige Yuji, Maeda Yoshikazu, Sasaki Makoto, Takamatsu Shigeyuki, Yamamoto Kazutaka

机构信息

Proton Therapy Center, Fukui Prefectural Hospital, 2-8-1 Yotsui, Fukui City 910-8526, Fukui Prefecture, Japan.

Department of Gastroenterology, Fukui Prefectural Hospital, 2-8-1 Yotsui, Fukui City 910-8526, Fukui Prefecture, Japan.

出版信息

Cancers (Basel). 2023 Jan 30;15(3):860. doi: 10.3390/cancers15030860.

Abstract

We evaluated elective nodal irradiation (ENI) doses during radical chemoradiotherapy (CRT) for esophageal cancer (EC). A total of 79 patients (65 men and 14 women) aged 52-80 years with T1-3, N0-3, and M0 (including M1ly) who underwent CRT for EC during November 2012-September 2019 were eligible for this retrospective analysis. Patients were divided into two groups: the high-dose group (HG), including 38 patients who received ≥40 Gy as ENI; and the low-dose group (LG), including 41 patients who received <40 Gy. The median doses were 40.0 and 36.0 Gy in HG and LG, respectively. During the follow-up (median: 36.7 months), no lymph node recurrence was observed in the ENI field in all patients. Lymph node recurrence near the ENI field was observed in six patients. No significant differences were observed between the two groups in median overall survival, progression-free survival, and local control. Grade 3-4 acute and late adverse events were observed in five patients of HG and six patients of LG, respectively. No ulceration or stricture was observed in the ENI field on endoscopy examined with 58 Gy irradiation. In conclusion, an ENI dose of 36 Gy could be considered to control the elective nodes of EC.

摘要

我们评估了食管癌(EC)根治性放化疗(CRT)期间的选择性淋巴结照射(ENI)剂量。2012年11月至2019年9月期间,共有79例年龄在52 - 80岁、T1 - 3、N0 - 3和M0(包括M1ly)的食管癌患者接受了CRT,这些患者符合本次回顾性分析的条件。患者分为两组:高剂量组(HG),包括38例接受ENI剂量≥40 Gy的患者;低剂量组(LG),包括41例接受ENI剂量<40 Gy的患者。HG组和LG组的中位剂量分别为40.0 Gy和36.0 Gy。在随访期间(中位时间:36.7个月),所有患者的ENI区域均未观察到淋巴结复发。6例患者在ENI区域附近观察到淋巴结复发。两组在中位总生存期、无进展生存期和局部控制方面均未观察到显著差异。HG组有5例患者、LG组有6例患者发生了3 - 4级急性和晚期不良事件。接受58 Gy照射的患者在内镜检查中,ENI区域未观察到溃疡或狭窄。总之,36 Gy的ENI剂量可被认为能控制食管癌的选择性淋巴结。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验